Mycoplasma pulmonis in pet rats: chronic respiratory disease, treatment, and prognosis

Bottom line

Murine respiratory mycoplasmosis — the chronic respiratory disease (CRD) complex of the pet rat — is managed, not cured. Mycoplasma pulmonis persists for life and antimicrobials reduce signs without clearing it: "treatment with antimicrobials can alleviate clinical signs of CRD in rats; however, it does not eliminate the infection" [1], and "in general, chronic infections are difficult if not impossible to eliminate with antibiotics, although disease severity can be reduced" [2]. Expect relapse on withdrawal, treat the environment as seriously as the organism, and have the chronic-management conversation at the first visit, not the third.

Signalment and presentation

Any pet rat, any age, either sex; among 375 pet rats recorded over six months at three French centres, rhinitis was one of the three commonest diagnoses [3]. Merck's professional rodent chapter notes that "initial infection commonly occurs without any clinical signs," with early signs including "snuffling, nasal discharge, polypnea, weight loss, hunched posture, ruffled coat, head tilt, and red tears" [1]; Schoeb adds that "progression to severe bronchopulmonary disease can lead to weight loss, dyspnea, and, rarely, death" [2].

Porphyrin is not blood. Red-brown crusting at nares and medial canthi is chromodacryorrhoea: "Harderian glands next to the orbits secrete porphyrins, lipids and other compounds," and "high levels of secretion lead to chromodacryorrhoea (red or 'bloody' tears), often taken as a sign of stress or disease" [4]. Investigate it; never work it up as haemorrhage.

Head tilt means otitis media/interna — but do not assume the organism. Chronic disease "often includes middle ear infection (via the eustachian tube)" [1], and among 23 companion rats with otitis media/interna diagnosed 2011–2025, eighteen had concurrent respiratory disease and seven had intracranial extension (meningoencephalitis or rhombencephalitis) [5]. In that same series, though, "bacterial culture (14/23) of lung, ear and/or brain samples revealed various bacteria, including Staphylococcus aureus (3/14)," and "Mycoplasma was identified in six cases (three via PCR, two via culture and one via next-generation sequencing)" [5] — six of 23, not most. Image early and culture the ear where you can reach it, rather than defaulting to mycoplasma-directed therapy. Late disease is structural — bronchiectasis, bronchopneumonia, atelectasis, abscessation — which no antimicrobial reverses.

Pathogenesis: M. pulmonis rarely acts alone

M. pulmonis is "the major component of CRD" [1], but the clinical picture is a consortium. One survey of pet ratteries in the northwestern US "showed virtually all (95%) were positive for F rodentium and M pulmonis, and approximately half were positive for other viral respiratory agents" [1]. Merck lists the factors governing disease expression in one sentence: "intracage ammonia levels; concurrent infection with Sendai virus, coronavirus (sialodacryoadenitis virus), pneumonia virus of mice, rat respiratory virus, and/or F rodentium; genetic susceptibility of the host; virulence of the Mycoplasma strain; and vitamin A or E deficiency" [1]. Assume Filobacterium rodentium (formerly CAR bacillus) is present.

In gnotobiotic F344/N rats given M. pulmonis then Sendai virus a week later, mycoplasma alone induced "mild lesions of murine respiratory mycoplasmosis including mild to moderate suppurative rhinitis, otitis media, laryngitis, and tracheitis... but not lung lesions," whereas co-infected rats "had severe lesions characteristic of advanced mycoplasmal disease throughout the respiratory tract... some rats also had suppurative pneumonia and bronchiectasis" [6]. That is a gnotobiotic model, not pet-rat natural history — but it is the mechanism behind the stable rat that crashes a fortnight after a new cage-mate arrives.

Ammonia: the co-factor you can actually change

Intracage ammonia has the strongest experimental support and the lowest cost to fix.

Broderson, Lindsey and Crawford inoculated pathogen-free Sherman and Fischer (F344) rats intranasally with 10^8 colony-forming units of M. pulmonis and housed them four to six weeks at ammonia concentrations from 25 to 250 ppm; "all levels of NH3 significantly increased the severity of the rhinitis, otitis media, tracheitis, and pneumonia (including bronchiectasis)" [7]. Ammonia without M. pulmonis caused lesions "unlike those of MRM and were limited to the nasal passages" [7] — it potentiates rather than merely irritates. It also raises burden: in rats exposed to ≤1.5 or 76 micrograms of NH3 per litre (≤2 or 100 ppm), "growth of M. pulmonis was much greater in NH3-exposed rats than in controls" [8]. Infection also primes the airway, and ammonia amplifies that as well. In pathogen-free F344 rats housed four weeks in ammonia-free air or air containing 100 ppm ammonia, infection caused "a potent, long-lasting potentiation of neurogenic inflammation"; "exposure of the infected rats to ammonia exacerbated the infections... and made the rats so sensitive to capsaicin that a normally tolerable dose of 150 micrograms/kg i.v. caused fatal apnea," whereas "ammonia did not have these effects in pathogen-free rats" [9].

These are controlled-chamber laboratory studies; nobody has measured ppm in a client's cage. The direction is unambiguous, and yields two instructions: change soiled bedding far more often, and ventilate without a draught.

Diagnosis: usually presumptive, and that is defensible

A definitive antemortem diagnosis is uncommon and usually unnecessary — "the organism can be safely assumed to be either the primary cause or a major contributory pathogen in most cases of chronic respiratory disease in rats" [2].

• PCR detects carriage, not causation: M. pulmonis was found on oropharyngeal swabs in 86 of 122 pet rats (70.49%) sampled irrespective of clinical status [10]. In a laboratory colony of 36 Wistar rats, signs "were observed in only 2 of 36 infected animals," yet "all the animals were found to be carrier after necropsy and PCR assay" [11] — a research colony, not a pet population, but the point holds.
• Serology and culture. Serology "sometimes fails to detect subclinical infections" [2]; in a near-universally exposed population a titre documents exposure. Culture on mycoplasma medium is readily successful [2] but belongs to colony surveillance.
• Radiography excludes differentials rather than confirming mycoplasmosis. Across 30 dyspnoeic companion rats (23 infectious, seven neoplastic), mediastinal lesions were significantly more prevalent with neoplasia (P = 0.031), particularly cranially (P = 0.048); the authors concluded that "although there was an overlap between the two groups, findings indicated that the presence of cranial mediastinal lesions may be helpful for differentiating neoplastic from infectious disease in rats" [12]. Thymoma is the mimic that matters.

Build the diagnosis from chronicity, airway signs, exclusion of neoplasia and cardiac disease, and response to therapy — reasoning that, documented, beats a PCR result that 70% of pet rats give regardless of clinical status.

Antimicrobial therapy

No agent eradicates the organism, and every one below is extra-label in the rat. The two sources that publish doses differ in species specificity, so the source column matters as much as the figure.

Agent	Dose exactly as published	Source
Enrofloxacin	10 mg/kg PO every 12 hours for 14 days	Merck, stated for rats [1]
Doxycycline	5–10 mg/kg PO every 12 hours for 14 days	Merck, stated for rats [1]
Doxycycline (relapse prevention)	5–10 mg/kg PO every 24 hours	Merck, stated for rats [1]
Enrofloxacin	5–10 mg/kg PO, SC or IM every 12 hours; or 50–200 mg/L drinking water	Schoeb, generic rodent table [2]
Doxycycline	5 mg/kg PO every 12 hours	Schoeb, generic rodent table [2]
Tylosin	10 mg/kg SC daily	Schoeb, generic rodent table [2]
Oxytetracycline	60 mg/kg IM every 3 days; 100 mg/kg SC daily; 3 g/L drinking water	Schoeb, generic rodent table [2]

Merck's three rows are stated for rats. Schoeb's four come from Table 1, "Selected Antibiotics," a generic rodent table in a review spanning mice, rats, guinea pigs and Syrian hamsters, carrying no per-species column, row or footnote — so they are not rat-specific published doses.

Three caveats follow. The doxycycline difference (Merck's 5–10 mg/kg q12h for rats against 5 mg/kg q12h in a generic rodent table) is not a rat-versus-rat disagreement between two rat authorities, and neither figure has been merged into the other. Fourteen days is the only duration either source states, and neither states one for chronic low-dose doxycycline. Neither source publishes a doxycycline-plus-enrofloxacin combination protocol or a combination dose, so none appears here. Azithromycin is carried in exotic companion mammal formularies (Carpenter's Exotic Animal Formulary; Quesenberry & Carpenter's Ferrets, Rabbits, and Rodents) and is reasonable when tetracyclines and fluoroquinolones fail; no figure appears here because none of these sources states one.

Supportive and anti-inflammatory care

Merck makes bronchodilation central: "bronchodilators are the primary treatment for the inflammatory aspect of CRD in rats and mice; they can be provided either orally (theophylline at 10 mg/kg, every 12 hours as needed) or as an aerosol (albuterol, also known as salbutamol, at 100 mcg/rat in a small chamber, every 4–6 hours)" [1]. It also recommends "daily nebulization therapy with 7% hypertonic saline to break down the mucus biofilm in respiratory passages, and daily removal of soiled bedding to decrease ammonia levels in cages" [1].

Suppressing airway inflammation has experimental support: in F344 rats given dexamethasone (0.5 mg/kg intraperitoneally) or oxytetracycline (20 mg/kg intramuscularly), "after 4 wk of treatment with oxytetracycline or dexamethasone, the chronic inflammation was nearly resolved and the response to substance P was in the normal range" [13] — laboratory doses and routes, so read them as the biological argument, not a protocol. Practice is more conservative: in the otitis media/interna series, 17 of 23 rats received antibiotics, 7 meloxicam, 3 corticosteroids, 2 myringotomy [5]. For the dyspnoeic rat: oxygen, minimal handling, and a weight every visit.

Prognosis and what to tell the owner

Merck reports that "in a retrospective study, rats with dyspnea of bacterial etiology lived 6–44 months (median 24 months)" [1]; the chapter does not say whether that ran from presentation or is age at death, so quote it as a spread, not a survival estimate. In the otitis media/interna series "survival ranged from 0 to 341 days" [5] — but read that range with care. "Twelve were diagnosed via necropsy alone, nine via imaging alone and two via both imaging and necropsy" [5], so 14 of 23 diagnoses involved necropsy and the zero lower bound is set by the inclusion criteria rather than by how the disease behaves. There is no comparator or untreated arm, and the study exists precisely because "there is limited information on treatment and prognosis in pet rats" [5].

The day-one script: the infection is lifelong; treatment buys symptom control and slows structural damage; signs return when antimicrobials stop, which is expected rather than failure; husbandry is therapy, not an extra. Euthanasia becomes the humane answer when dyspnoea at rest stops responding to bronchodilators and oxygen, when weight loss continues despite treatment, when a vestibular rat can no longer right itself or eat, or when relapses run together — raise it early, as part of the plan.

Prevention and husbandry

Husbandry here is disease-modifying therapy: "owners must combine frequent bedding changes with good husbandry practices, such as regular cage cleaning, low animal density, and low environmental temperature and humidity" [1].

• Bedding change frequency first — soiled substrate is the ammonia source, and ammonia worsens every lesion of this disease [7] and increases organism growth [8].
• Ventilation without draught — wire-topped cages rather than glass tanks; airflow across the room, not onto the cage.
• Lower stocking density — fewer rats per unit volume, less urine per unit volume.
• Substrate — paper-based or kiln-dried over aromatic softwood shavings; conventional guidance, not settled by the sources above.
• Quarantine new arrivals; remove aerosolised irritants (smoke, scented sprays, dusty litters).

Be honest about the ceiling: 95% of surveyed pet ratteries were positive for both F rodentium and M pulmonis [1] and 70.49% of pet rats swabbed PCR-positive [10]. A mycoplasma-free household is not realistic; quarantine targets the viral co-pathogens.

Frequently Asked Questions

Can Mycoplasma pulmonis be eradicated from an individual pet rat? No. Antimicrobials alleviate clinical signs but do not eliminate the infection [1], and "in general, chronic infections are difficult if not impossible to eliminate with antibiotics, although disease severity can be reduced" [2].

How long should I treat, and can I stop? Fourteen days is the only duration these sources publish — enrofloxacin at 10 mg/kg or doxycycline at 5–10 mg/kg, both PO every 12 hours [1]. For recurrent relapsers Merck describes chronic low-dose doxycycline at 5–10 mg/kg PO every 24 hours, with no stated end point [1]. Warn owners that some rats go back on.

My patient has a head tilt — is that still mycoplasma? Often, but do not assume it. Chronic CRD often includes middle ear infection via the eustachian tube [1], and of 23 companion rats with otitis media/interna, eighteen had concurrent respiratory disease and seven had intracranial extension [5]. But Mycoplasma was identified in only six of those cases, while bacterial culture of lung, ear and/or brain samples in 14 of 23 grew various bacteria including Staphylococcus aureus in 3 of 14 [5]. Radiograph the chest, culture the ear where feasible, and consider advanced imaging before committing to mycoplasma-directed therapy.

Does a positive Mycoplasma PCR confirm the diagnosis? It confirms carriage. PCR on oropharyngeal swabs was positive in 86 of 122 pet rats (70.49%) sampled regardless of signs [10], and in a laboratory colony all 36 rats were carriers while only 2 showed classical signs [11]. Diagnosis stays clinical and exclusionary.

How much does cage hygiene really matter? It has the strongest experimental support of anything on this page, and the lowest cost to fix. Ammonia at every concentration from 25 to 250 ppm significantly increased the severity of rhinitis, otitis media, tracheitis and pneumonia including bronchiectasis in experimentally infected rats [7], and increased M. pulmonis growth versus controls [8]. In pet rats, an inappropriate environment was a risk factor for respiratory disease (P < 0.001) among 375 cases [3].

Can my client catch it from their rats? Unresolved. M. pulmonis was detected by PCR in 21 of 86 pet rat keepers (24.42%), yet the authors concluded it is unknown whether its presence in humans is associated with disease [10]. No human disease is established — counsel routine hygiene, and refer immunocompromised owners to their physician.